Charlotte L. Smith

Paris, France

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications

TLX1 translocation variants and enhancer hijacking influence clinical outcome in T-cell acute lymphoblastic leukemia.

TLX1 translocation variants and enhancer hijacking influence clinical outcome in T-cell acute lymphoblastic leukemia.

Journal: HemaSphere
Published: August 08, 2025

Oncogenomic profiling in infant-toddler T-ALL identifies NKX2 family genes as drivers linked to favorable outcomes.

Oncogenomic profiling in infant-toddler T-ALL identifies NKX2 family genes as drivers linked to favorable outcomes.

Journal: HemaSphere
Published: February 26, 2025

Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL).

Towards methylation-based redefinition of TAL1 positive T-cell acute lymphoblastic leukaemia (T-ALL).

Journal: Leukemia
Published: January 28, 2025

Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL.

Surface pTα expression predicts LCK activation and preclinical synergy of LCK and JAK coinhibition in adult T-ALL.

Journal: Blood
Published: December 06, 2024

Neo-enhancers in T-cell acute lymphoblastic Leukaemia (T-ALL) and beyond.

Neo-enhancers in T-cell acute lymphoblastic Leukaemia (T-ALL) and beyond.

Journal: International journal of cancer
Published: August 16, 2024

DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma.

DNA methylation as a new tool for the differential diagnosis between T-LBL and lymphocyte-rich thymoma.

Journal: The Journal of pathology
Published: October 20, 2023

PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.

PHF6-altered T-ALL Harbor Epigenetic Repressive Switch at Bivalent Promoters and Respond to 5-Azacitidine and Venetoclax.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research
Published: July 18, 2023

TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2.

TREC mediated oncogenesis in human immature T lymphoid malignancies preferentially involves ZFP36L2.

Journal: Molecular cancer
Published: March 17, 2023

Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.

Harnessing the MYB-dependent TAL1 5'super-enhancer for targeted therapy in T-ALL.

Journal: Molecular cancer
Published: November 21, 2022

IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition.

IL-7 receptor expression is frequent in T-cell acute lymphoblastic leukemia and predicts sensitivity to JAK inhibition.

Journal: Blood
Published: July 29, 2022

TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.

TAL1 activation in T-cell acute lymphoblastic leukemia: a novel oncogenic 3' neo-enhancer.

Journal: Haematologica
Published: June 16, 2022

PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.

PRC2 loss of function confers a targetable vulnerability to BET proteins in T-ALL.

Journal: Blood
Published: December 04, 2020
Showing 1-12 of 18

Last Updated: 09/26/2026